	US 12,239,618 B2
	Histone acetyltransferase activators and compositions and uses thereof
Owen Anthony O'Connor, Scarsdale, NY (US); Jennifer Effie Amengual, Scarsdale, NY (US); Donald W. Landry, New York, NY (US); Ottavio Arancio, New York, NY (US); Luigi Scotto, Stamford, CT (US); Shixian Deng, White Plains, NY (US); Rosa Purgatorio, Bari (IT); and Jole Fiorito, Floral Park, NY (US)
Assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US)
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed on Aug. 4, 2022, as Appl. No. 17/881,340.
Application 16/870,584 is a division of application No. 15/655,583, filed on Jul. 20, 2017, granted, now 10,653,648, issued on May 19, 2020.
Application 17/881,340 is a continuation of application No. 16/870,584, filed on May 8, 2020, granted, now 11,406,608.
Claims priority of provisional application 62/364,480, filed on Jul. 20, 2016.
Prior Publication US 2023/0165813 A1, Jun. 1, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/167 (2006.01); A61K 31/18 (2006.01); A61K 31/381 (2006.01); A61K 31/4035 (2006.01); A61K 31/44 (2006.01); A61K 31/4409 (2006.01); A61K 31/4453 (2006.01); A61K 31/495 (2006.01); A61K 31/505 (2006.01); A61K 31/535 (2006.01); A61K 31/5377 (2006.01); A61K 38/15 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/167 (2013.01) [A61K 31/18 (2013.01); A61K 31/381 (2013.01); A61K 31/4035 (2013.01); A61K 31/44 (2013.01); A61K 31/4409 (2013.01); A61K 31/4453 (2013.01); A61K 31/495 (2013.01); A61K 31/505 (2013.01); A61K 31/535 (2013.01); A61K 31/5377 (2013.01); A61K 38/15 (2013.01); A61K 45/06 (2013.01)]

14 Claims

1. A method for treating a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a HAT activator and a HDAC inhibitor, wherein the HAT activator is:

or a pharmaceutically acceptable salt thereof, the HDAC inhibitor is romidepsin, and wherein the neurodegenerative disease is Alzheimer's Disease.